1
|
Alalshaikh M, Almalki Y, Hasanato R, Almomen A, Alsughayir A, Alabdullateef A, Sabbar A, Alsuhaibani O. Frequency of Rh and K antigens in blood donors in Riyadh. Hematol Transfus Cell Ther 2021; 44:555-559. [PMID: 33992594 PMCID: PMC9605887 DOI: 10.1016/j.htct.2021.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 01/17/2021] [Accepted: 03/17/2021] [Indexed: 11/05/2022] Open
Abstract
Objectives Investigate the prevalence of Rh and the K antigens and their phenotypes in the red blood cells of blood donors in Riyadh, Saudi Arabia. Methods This is a retrospective study. The five principal Rh antigens (D, C, c, E, e) and the Kell antigen from the Kell blood group were tested in 4,675 random samples collected from four blood bank centers in Riyadh. Data were collected for seven weeks (from January 4, 2019 to February 28, 2019). Antigens were tested using the TANGO Optimo system. Results We found that approximately 86% of the donors had the D antigen, 66% had C, 78% had c, 26% had E, 97% had e and 14% had K. The most common Rh phenotypes were R1r (31%) and R1R1 (22%). Conclusion The differences in the results between the study population and other populations, such as Caucasian, Indian and African populations indicate the importance of establishing a population-specific database.
Collapse
|
2
|
Owaidah T, Al-Numair N, Al-Suliman A, Zolaly M, Hasanato R, Al Zahrani F, Albalawi M, Bashawri L, Siddiqui K, Alalaf F, Almomen A, Sajid MR. Iron Deficiency and Iron Deficiency Anemia Are Common Epidemiological Conditions in Saudi Arabia: Report of the National Epidemiological Survey. Anemia 2020; 2020:6642568. [PMID: 33936813 PMCID: PMC8056870 DOI: 10.1155/2020/6642568] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 12/08/2020] [Accepted: 12/16/2020] [Indexed: 11/18/2022] Open
Abstract
Iron deficiency is the most prevalent nutritional deficiency worldwide. According to an estimate by the World Health Organization, up to 27% of the world's population experience iron deficiency anemia (IDA). Studies conducted in the Middle East, including Saudi Arabia, have suggested that IDA is the most common cause of anemia, especially among females. This study aimed to determine the prevalence of IDA and iron deficiency (ID) among apparently healthy young university students from four regions in Saudi Arabia. Students were asked to complete a simple survey questionnaire; blood samples were then collected and analyzed after obtaining informed consent. A total of 981 students completed the survey, with 11% of the participants reporting symptoms of anemia; 34% of participants were diagnosed with IDA and 6% reported a diagnosis of hemoglobinopathy. Blood analysis confirmed the prevalence of ID and IDA in 28.6% and 10.7% of the participants, respectively; those with ID and IDA were mostly females (88.5% and 94%, resp.). Thalassemia trait and sickle cell trait were detected in 1.3% and 7% of participants, respectively. Our findings from a national survey among young university in Saudi Arabia indicate a high prevalence of ID and IDA.
Collapse
Affiliation(s)
- Tarek Owaidah
- Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & RC, Alfaisal University, Riyadh 11211, Saudi Arabia
| | - Nouf Al-Numair
- Research Center, King Faisal Specialist Hospital, Alfaisal University, Riyadh 11211, Saudi Arabia
| | - Ayman Al-Suliman
- Research Center, King Faisal Specialist Hospital, Alfaisal University, Riyadh 11211, Saudi Arabia
| | - Mohammed Zolaly
- Department of Pediatric Hematology, College of Medicine, Taibah University, Medina, Saudi Arabia
| | - Rana Hasanato
- Department of Pathology, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia
| | - Faisal Al Zahrani
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Mohameed Albalawi
- Department of Internal Medicine, Taibah University, Medina, Saudi Arabia
| | - Layla Bashawri
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Khawar Siddiqui
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital, Riyadh 11211, Saudi Arabia
| | - Faisal Alalaf
- Department of Medical Genetics, Umm Al-Qura University Faculty of Medicine, Makkah, Saudi Arabia
| | - Abdulkareem Almomen
- Department of Pathology, College of Medicine, King Saud University, Riyadh 12372, Saudi Arabia
| | | |
Collapse
|
3
|
Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Subramanian K, D'Souza F, Viswabandya A, Hoorfar H, Schwartz BA, Solomon C, Knaub S, Peyvandi F. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost 2020; 18:815-824. [PMID: 31885190 PMCID: PMC7187153 DOI: 10.1111/jth.14727] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 12/19/2019] [Accepted: 12/26/2019] [Indexed: 01/19/2023]
Abstract
BACKGROUND Congenital fibrinogen deficiency is an ultra-rare disorder in which patients can experience severe and/or frequent bleeding episodes (BEs). Here, we present the largest prospective study to date on the treatment of this disorder. METHODS Hemostatic efficacy of human fibrinogen concentrate (HFC; FIBRYGA® , Octapharma AG) for treatment of bleeding or surgical prophylaxis was assessed by investigators and adjudicated by an independent data monitoring and endpoint adjudication committee (IDMEAC) according to a four-point scale, using objective criteria. Thromboelastometry maximum clot firmness (MCF) was also determined. RESULTS Twenty-five afibrinogenemia patients were treated with HFC: 24 for on-demand treatment of 89 BEs, and nine as prophylaxis for 12 surgeries. For BEs, treatment success (rating of excellent or good) evaluated by investigators was 96.6% (90% confidence interval [CI], 0.92-0.99; two missing ratings, classified as failures) and by the IDMEAC was 98.9% (90% CI, 0.95-0.999). Mean ± standard deviation (SD) increase in MCF was 5.8 ± 2.5 mm one hour after the first HFC infusion (mean ± SD dose, 61.88 ± 11.73 mg/kg). For the 12 surgeries (median [range] HFC dose/surgery, 85.80 mg/kg [34.09-225.36]), intraoperative and postoperative treatment success were both rated 100% (90% CI, 0.82-1.00) by investigators and the IDMEAC. Three adverse events were possibly treatment related, including a moderate case of thrombosis. There were no deaths, no severe allergic or hypersensitivity reactions, and no clinical evidence of neutralizing antifibrinogen antibodies. CONCLUSIONS Human fibrinogen concentrate was efficacious for on-demand treatment of bleeding and as surgical prophylaxis, with a favorable safety profile, in patients with congenital afibrinogenemia.
Collapse
Affiliation(s)
- Toshko Lissitchkov
- Department of Hemorrhagic Diathesis and AnemiaSpecialized Hospital for Active Treatment (SHAT) “Joan Pavel”SofiaBulgaria
| | - Bella Madan
- Centre for Haemostasis & ThrombosisGuy's & St Thomas' NHS Foundation TrustLondonUK
| | | | - Nadezhda Zozulya
- Federal State‐Funded Institution “National Research Center for Hematology” of the Ministry of Healthcare of the Russian FederationMoscowRussia
| | - Cecil Ross
- Department of HematologySt. John's Medical College & HospitalBangaloreIndia
| | | | | | | | - Abdulkareem Almomen
- Centre of Excellence in Thrombosis & HemostasisCollege of Medicine and King Khalid University HospitalKing Saud UniversityRiyadhSaudi Arabia
| | | | - Fulton D'Souza
- Department of HematologySt. John's Medical College & HospitalBangaloreIndia
| | | | | | | | | | - Sigurd Knaub
- Research & Development DepartmentOctapharmaLachenSwitzerland
| | - Flora Peyvandi
- Angelo Bianchi Bonomi Hemophilia and Thrombosis CenterFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoMilanItaly
- Department of Pathophysiology and TransplantationUniversità degli Studi di MilanoMilanItaly
| |
Collapse
|
4
|
Yang C, Unice C, Almomen A, Janát-Amsbury M. Comparative assessment of clinical progestin formulations in a murine model of endometrial hyperplasia. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Tarawah A, Owaidah T, Al-Mulla N, Khanani M, Elhazmi J, Albagshi M, Wali Y, AlMohareb S, Almomen A. Management of Glanzmann's Thrombasthenia – Guidelines based on an expert panel consensus from gulf cooperation council countries. J Appl Hematol 2019. [DOI: 10.4103/joah.joah_68_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
6
|
Alsaleh K, Aleem A, Almomen A, Anjum F, S Alotaibi G. Impact of Day 14 Bone Marrow Biopsy on Re-Induction
Decisions and Prediction of a Complete Response in Acute
Myeloid Leukemia Cases. Asian Pac J Cancer Prev 2018; 19:421-425. [PMID: 29479992 PMCID: PMC5980929 DOI: 10.22034/apjcp.2018.19.2.421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Background: With acute myeloid leukemia (AML), there are limited data about the accuracy of day 14 bone
marrow (BM) biopsies for predicting complete remission as compared to day 28 BM biopsy results. We here aimed
to estimate the correlation between, and the diagnostic accuracy of, both approaches. Materials and Methods: We
reviewed 84 patients with AML treated with standard induction chemotherapy to evaluate the remission rate and
treatment decisions based on day 14 BM biopsy from 2000-2012. Results: Sixty five patients (77%) demonstrated
remission (CR) with less than 5% blasts on their day 14 BM. Thirteen patients (16%) had residual disease (RD), and
6 (7%) were classified as indeterminate response (IR) i.e., blasts 5-20%. Two patients with RD on day 14 underwent
re-induction. Out of the 17 remaining cases with RD+IR, 14 (all 6 with IR and 8 out of 11 with residual disease with
no re-induction) demonstrated a morphologic complete remission (CR) on day 28 BM. The percentages for complete
remissions on days 28 and 14 were significantly different [94% versus 79.3%, respectively; p=0.004, (OR= 0.143, 95%
CI: 0.032-0.63)]. Day 14 BM had 82% sensitivity in predicting CR on Day 28; however, it had insufficient specificity
(60%) in predicting failure of CR. Conclusions: Induction treatment response assessment based on day 14 BM does
not accurately predict the response rate on day 28 and the use of day 14 BM as a sole marker of response to therapy
might expose patients to unnecessary interventions.
Collapse
|
7
|
Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, Peyvandi F. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion 2017; 58:413-422. [DOI: 10.1111/trf.14421] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 09/22/2017] [Accepted: 09/27/2017] [Indexed: 01/19/2023]
Affiliation(s)
- Toshko Lissitchkov
- Department of Hemorrhagic Diathesis and Anemia; Specialized Hospital for Active Treatment (SHAT) “Joan Pavel,”; Sofia Bulgaria
| | - Bella Madan
- Centre for Haemostasis & Thrombosis; Guy's & St Thomas' NHS Foundation Trust; London UK
| | | | - Nadezhda Zozulya
- Federal State-Funded Institution “National Research Center for Hematology” of the Ministry of Healthcare of the Russian Federation; Moscow Russia
| | - Cecil Ross
- Department of Hematology; St John's Medical College & Hospital; Bangalore India
| | - Mehran Karimi
- Hematology Research Center, Nemazee Hospital; Shiraz University of Medical Sciences; Shiraz Iran
| | - Kaan Kavakli
- Ege University, Children's Hospital; Izmir Turkey
| | | | - Abdulkareem Almomen
- Centre of Excellence in Thrombosis & Hemostasis; College of Medicine and King Khalid University Hospital, King Saud University; Riyadh Saudi Arabia
| | | | - Cristina Solomon
- Research & Development Department; Octapharma; Lachen Switzerland
- Department of Anesthesiology, Perioperative Care and General Intensive Care; Paracelsus Medical University, Salzburg University Hospital; Salzburg Austria
| | - Sigurd Knaub
- Research & Development Department; Octapharma; Lachen Switzerland
| | - Flora Peyvandi
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Luigi Villa Foundation, Department of Pathophysiology and Transplantation; Università degli Studi di Milano; Milan Italy
| |
Collapse
|
8
|
Aleem A, Alsaleh K, Aljabry M, Aziz S, Iqbal Z, Almomen A. A comparison of two techniques of preparing bone marrow aspirate slides. J PAK MED ASSOC 2016; 66:528-7. [PMID: 27183929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE To compare direct smear technique with ethylenediaminetetraacetic acid (EDTA) preserved smear technique in terms of preparing bone marrow aspirate slides. METHODS This prospective study was carried out between September 2009 and July 2012 at the Haematology/Oncology Department, King Khalid University Hospital, Riyadh, Saudi Arabia. With a standard gauge disposable bone marrow aspirate needle, 0.5 to 1.0 ml bone marrow was aspirated with a 10ml syringe. Half of the marrow was immediately transferred to an EDTA tube with gentle mixing, while slides were prepared directly from the rest of the sample in the syringe. The tube sample was used to prepare slides at the end of the procedure. A score of 1-4 was assigned to each slide depending on the quality and number of particles. RESULTS A total of 245 bone marrow aspirate samples were evaluated related to 216 patients. Of the total, 238 (97%) samples were included in the study. The mean score for the direct smear group was 3.40±0.79 and for the EDTA smear group it was 3.34±0.75 (p=0.27), which was not statistically significant. An informal comparison of the morphological analysis of the samples did not reveal any differences. CONCLUSIONS Bone marrow aspirate slides prepared at the end of the procedure from EDTA preserved samples were not inferior to slides prepared directly from the aspirated sample.
Collapse
Affiliation(s)
- Aamer Aleem
- Department of Medicine, Division of Haematology/Oncology, Riyadh, Saudi Arabia
| | - Khalid Alsaleh
- Department of Medicine, Division of Haematology/Oncology, Riyadh, Saudi Arabia
| | - Mansour Aljabry
- Department of Pathology, Division of Haematopathology, Riyadh, Saudi Arabia
| | - Shahid Aziz
- Department of Emergency Medicine, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
| | - Zafar Iqbal
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University of Health Sciences, Riyadh, Saudi Arabia
| | - Abdulkareem Almomen
- Department of Medicine, Division of Haematology/Oncology, Riyadh, Saudi Arabia
| |
Collapse
|
9
|
Aleem A, Anjum F, Algahtani F, Iqbal Z, Alsaleh K, Almomen A. Clofarabine in the treatment of elderly patients with acute myeloid leukemia. Asian Pac J Cancer Prev 2014; 14:1089-92. [PMID: 23621192 DOI: 10.7314/apjcp.2013.14.2.1089] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Elderly patients with acute myeloid leukemia (AML) have a poor outcome because of co- morbidities, poor tolerance to intensive chemotherapy and inherently more resistant disease. Clofarabine is a second generation nucleoside analogue which has shown promising activity in elderly patients with AML. This study was conducted to review the outcome of treatment with clofarabine in a group of such patients. METHODS The records of 5 elderly patients who were diagnosed to have AML and treated with clofarabine over a 12 month period were reviewed retrospectively. RESULTS There were 2 female and 3 male patients with a median age of 68 years (range 65-82). At the time of treatment, 2 patients had newly diagnosed AML not considered suitable for intensive therapy, while 3 patients had partial or no response to conventional chemotherapy. The overall response rate was 100%, all patients achieving a complete remission. Induction and consolidation were well tolerated. All patients developed neutropenia with a median duration of 20 days (range 17-42). One patient developed hand and foot syndrome and a generalized rash but recovered. There was no mortality and all patients remained in remission after a median follow-up of 5.2 months (Range 3-10). CONCLUSION Clofarabine (alone or in combination) is active in elderly AML patients with an acceptable safety profile and should be considered a potential option in this group.
Collapse
Affiliation(s)
- Aamer Aleem
- Department of Medicine, Division of Hematology /Oncology, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
| | | | | | | | | | | |
Collapse
|
10
|
Almomen A, Farhan S, Afzal A, Al Khaledy O. Gingival hypertrophy does not always mean leukemia. J Appl Hematol 2014. [DOI: 10.4103/1658-5127.142008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
11
|
Almomen A, Anjum F, Cana S, Sharif M. Extra medullary hematopoiesis. J Appl Hematol 2014. [DOI: 10.4103/1658-5127.137179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
12
|
Almomen A, Aleem A, Alshaik M, Hasanato R. Intrapulmonary rFVIIa for life threatening pulmonary hemorrhage in a case of relapsing acute lymphoblastic leukemia and platelet refractoriness. Platelets 2013; 25:452-4. [PMID: 24102447 DOI: 10.3109/09537104.2013.835797] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Platelet refractoriness may lead to life-threatening gastro-intestinal, intracranial or pulmonary hemorrhage that is difficult to control despite massive platelet and red cell transfusion, antifibrinolytic agents, high dose corticosteroids, immunoglobulin and intravenous (I.V.) recombinant activated factor VII (rFVIIa). In cases with pulmonary hemorrhage, intrapulmonary administration of rFVIIa may be more effective in non-responsive cases. We report a 51-year-old man with relapsing acute lymphoblastic leukemia (ALL) and platelet refractoriness, who suffered a life-threatening pulmonary hemorrhage that was refractory to massive platelet transfusion, tranexamic acid, high dose corticosteroids, immunoglobulin and intravenous rFVIIa, but responded immediately to a single intrapulmonary dose of rFVIIa that was inhaled with a jet nebulizer assistance through the endotracheal tube.
Collapse
Affiliation(s)
- Abdulkareem Almomen
- Center of Excellence in Thrombosis and Hemostasis, College of Medicine and King Khalid University Hospital, King Saud University , Riyadh , Saudi Arabia
| | | | | | | |
Collapse
|
13
|
Qari MH, Wali Y, Albagshi MH, Alshahrani M, Alzahrani A, Alhijji IA, Almomen A, Aljefri A, Al Saeed HH, Abdullah S, Al Rustumani A, Mahour K, Mousa SA. Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis 2013; 8:143. [PMID: 24044606 PMCID: PMC3848639 DOI: 10.1186/1750-1172-8-143] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Accepted: 09/06/2013] [Indexed: 11/24/2022] Open
Abstract
Thalassemia syndrome has diverse clinical presentations and a global spread that has far exceeded the classical Mediterranean basin where the mutations arose. The mutations that give rise to either alpha or beta thalassemia are numerous, resulting in a wide spectrum of clinical severity ranging from carrier state to life-threatening, inherited hemolytic anemia that requires regular blood transfusion. Beta thalassemia major constitutes a remarkable challenge to health care providers. The complications arising due to the anemia, transfusional iron overload, as well as other therapy-related complications add to the complexity of this condition. To produce this consensus opinion manuscript, a PubMed search was performed to gather evidence-based original articles, review articles, as well as published work reflecting the experience of physicians and scientists in the Arabian Gulf region in an effort to standardize the management protocol.
Collapse
Affiliation(s)
- Mohamad H Qari
- The Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|